Back to top
more

Agios Pharmaceuticals, Inc. (AGIO)

(Delayed Data from NSDQ)

$47.52 USD

47.52
270,973

-0.23 (-0.48%)

Updated Sep 24, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (215 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates

Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.

Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

    Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up

    Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.

    Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue?

    Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal

    Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

    Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD

    The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.

    Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss

    Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.

    Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU

    Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.

    All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy

    Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound?

    Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

    Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?

    Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.